Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy

Inclusion Criteria:

   1. Pregnant women between 20-28 weeks gestation.

   2. 18 years of age or older.

   3. Singleton gestation.

Exclusion Criteria:

   1. Preexisting morbidity: Immunocompromised status (HIV +; malignancy; history of organ
   transplant; chronic steroid therapy; autoimmune disease requiring treatment during
   pregnancy, and other immunocompromised states); Type 1 diabetes and type 2
   diabetes;congenital cardiac disease and cardiac valvular disease requiring antibiotic
   prophylaxis during procedure/labor; pulmonary disease (except mild asthma); renal
   disease; chronic hepatic disease (Hepatitis B, C); inflammatory bowel disease (Crohn's
   disease or ulcerative colitis); stomach or duodenal ulcer; bowel resection, gastric
   bypass, and chronic indwelling venous, bladder, or gastric catheter.

   2. Multi-fetal gestation.

   3. Use of probiotics preparations in the 3 months prior to beginning of the study
   treatment or use of any additional probiotics preparations (other than study
   treatment) at any time during the study period (including over the counter food
   supplements such as Activia, BioK, other oral or vaginal probiotics products (BUT not
   including other common forms of yogurt).

   4. Chronic (daily) use of broad spectrum antibiotics.

   5. History of infant with GBS sepsis.

   6. Intrauterine Growth Restriction (IUGR), Fetal Anomalies-major diagnosed at time of
   second trimester anatomy ultrasound

   7. Anticipated delivery <35 wks for maternal/fetal indication

   8. Placenta previa or accreta (with anticipated delivery prior to 35 weeks)